Citizens Financial Group
CFG
$65.38
+0.86%
Citizens Financial Group, Inc. is a Providence, Rhode Island-based bank holding company that operates through two reportable segments — Consumer Banking and Commercial Banking — providing deposits, mortgage and home equity lending, credit cards, small business and education loans, point-of-sale finance, wealth management, and middle-market and corporate lending through a branch and ATM network. With roughly 17,400 employees and a market capitalization near $25 billion, CFG is a large-cap regional bank whose identity is anchored in consumer-led deposit gathering and fee income rather than capital markets or trading, making it a relatively plain-vanilla spread-lending franchise. The current investor narrative centers on a powerful earnings recovery: Q3 2026 revenue of $3.27 billion was a record, net income rose to $636 million with EPS of $1.42, and the company has been aggressively repurchasing stock while expanding margins — a combination that has attracted value-oriented attention. That bullish case is tempered by credit-quality concerns flagged in recent coverage and by a stock that has given back a meaningful portion of its mid-year gains, leaving investors to debate whether the pullback is a buying opportunity or an early warning on the credit cycle.…
CFG
Citizens Financial Group
$65.38
Related headlines
Investment Opinion: Should I buy CFG Today?
Rating: Buy. The core thesis is that CFG is a recovering, consumer-led regional bank trading at 9.74x forward earnings and 0.96x book value while delivering record revenue ($3.268 billion in Q3 2026, +5.83% YoY) and 28.7% net income growth, with 17 of 19 analysts rating it Buy and an average target of $76.39 implying 20.8% upside from $63.24. The Street is defending the thesis through a 12.98% three-month drawdown rather than chasing price, which is a constructive setup for a value-oriented entry.
The supporting evidence is broad. Valuation is undemanding at 14.98x trailing and 9.74x forward earnings (a 35% compression implying EPS growth to the $5.74 consensus), with a 0.53 PEG ratio and 0.96x P/B below tangible book. Revenue has risen for three consecutive quarters ($3.026B → $3.195B → $3.268B) with interest income up to $2.621 billion while interest expense fell to $946 million, and net margin expanded to 19.46% from 16.00% a year ago. Free cash flow TTM of $1.093 billion implies a ~4.3% FCF yield, the 3.52% dividend is covered by a 48.5% payout ratio, and $356 million of Q3 capital return ($231M dividends, $125M buybacks) was funded internally while cash grew to $12.97 billion. The 20.8% implied upside to the $76.39 average target is the anchor.
The biggest risks are credit normalization (the $5.74 forward EPS is the load-bearing assumption), a multiple reversion toward the recent 11.2x–13.4x trailing band, and a 6.96% ROE that limits how much book-value re-rating is left after the move from 0.53x in Q2 2023 to 0.96x today. This Buy would upgrade to a higher-conviction stance if Q4 credit metrics stabilize and ROE moves toward 10%, and would downgrade to Hold if forward EPS estimates are cut or the stock breaks below the $62.57 October low. Verdict: fairly valued to modestly undervalued — cheap on forward earnings and book, but not a deep-value bargain given mid-single-digit returns.
Sign up to view all
CFG 12-Month Price Forecast
The forward-looking case is constructive but not high-conviction: CFG offers 20.8% implied upside to the analyst average target at a 9.74x forward multiple, backed by record revenue, expanding margins, and a well-covered 3.52% dividend. The main constraint is that the 0.96x book valuation already reflects the re-rating from the 0.53x Q2 2023 trough, so further gains must come from ROE improvement toward 10%+ rather than multiple expansion. The 12.98% three-month drawdown and explicit credit-quality warnings are the swing factor — if Q4 credit metrics stabilize, the stock likely grinds toward $76; if provisions rise, the forward EPS and the multiple compress together. I would upgrade to high confidence on evidence of stable credit and ROE above 8%, and downgrade to neutral on a break below the $62.57 October low or any cut to the $5.74 consensus.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Citizens Financial Group's 12-month outlook, with a consensus price target around $76.39 and implied upside of +16.9% versus the current price.
Average Target
$76.39
20 analysts
Implied Upside
+16.9%
vs. current price
Analyst Count
20
covering this stock
Price Range
$65 - $87
Analyst target range
Coverage is robust, with 19 analysts and a distribution of 17 Buy, 3 Hold, and 0 Sell — an overwhelmingly bullish consensus reflected in a recommendation mean of 1.55 and an overall "buy" rating. The average target price of $76.39 implies roughly 20.8% upside from the current $63.24, a meaningful gap that suggests the Street views the recent 13% three-month drawdown as an opportunity rather than a deterioration in fundamentals. Consensus EPS of $5.74 for the forward period underpins that view, and estimated revenue of $7.24 billion is consistent with the record top-line trajectory. The bullish tilt is broad-based and not the product of a single outlier. The target range runs from a low of $65.00 to a high of $87.00, a spread of about 34% of the current price — moderately wide, signaling real disagreement about the credit cycle rather than about the business model. The low target of $65.00 implies only 2.8% upside and effectively prices in flat-to-modest multiple expansion with credit normalization; the high target of $87.00 implies roughly 37.6% upside and assumes continued margin expansion, sustained buybacks, and a re-rating toward 1.2x+ book value. Institutional ratings show remarkable stability — Morgan Stanley, RBC, Cantor Fitzgerald, UBS, JP Morgan, and Evercore ISI all reiterated Overweight/Outperform/Buy positions in October 2026, while Stephens and Truist maintained Equal Weight/Hold — indicating no recent downgrades and a consensus that has held firm through the pullback. The tight clustering of bullish reiterations alongside a stock trading 16% below its 52-week high is a constructive signal: analysts are not chasing price, they are defending a thesis.
Bulls vs Bears: CFG Investment Factors
The bull case currently has stronger evidence: revenue is at a record with three consecutive sequential gains, net income is up 28.7% YoY with margins at their best level in the dataset, and 17 of 19 analysts rate the stock Buy with an average target implying 20.8% upside from $63.24. The bear case rests less on fundamentals than on trajectory — a 12.98% three-month drawdown, explicit credit-quality warnings, and a 6.96% ROE that leaves the 0.96x book valuation looking fair rather than cheap. The single most important tension is whether the $5.74 forward EPS consensus survives the credit cycle: at 9.74x forward earnings the stock is inexpensive if the recovery holds, but the 35% gap between trailing and forward multiples means any credit deterioration would compress the estimate and the multiple simultaneously. The wide $65–$87 target range confirms that this credit-cycle question, not the business model, is what divides the Street.
Bullish
- Record revenue with accelerating sequential growth: Q3 2026 revenue of $3.268 billion grew 5.83% YoY from $3.088 billion and marked the third consecutive sequential increase ($3.026B → $3.195B → $3.268B). The record top line is being driven by both spread and fee levers, with interest income up to $2.621 billion from $2.458 billion while interest expense fell to $946 million from $970 million.
- Profitability inflecting sharply: Net income rose 28.7% YoY to $636 million in Q3 2026 from $494 million, with net margin expanding to 19.46% from 16.00% and operating margin reaching 24.60% from 20.37%. EPS climbed to $1.42 from $1.06, and the quarterly net income progression ($373M → $436M → $494M → $528M → $517M → $587M → $636M) shows a remarkably consistent upward trajectory.
- Forward PE of 9.74x implies cheap recovery: The stock trades at 14.98x trailing but only 9.74x forward earnings, a 35% compression that implies the market expects EPS to grow from roughly $4.22 trailing to the $5.74 consensus. A 0.53 PEG ratio and 0.96x price-to-book — below tangible book — suggest the market is not yet paying for the earnings recovery.
- Overwhelming analyst consensus with 20.8% upside: Of 19 analysts, 17 rate Buy and none rate Sell, producing a recommendation mean of 1.55 and an average target of $76.39 versus the $63.24 current price. The high target of $87.00 implies 37.6% upside, and Morgan Stanley, RBC, UBS, JP Morgan, and Evercore ISI all reiterated bullish positions in October 2026 despite the pullback.
Bearish
- Three-month drawdown of 13% signals fading momentum: Despite a 24.24% one-year gain, the stock is down 12.98% over three months and has failed to hold the July–August highs near $74.73, sitting at just 54.6% of its 52-week range. The 3-month relative strength versus SPY of -8.07 points shows CFG underperforming the market during the correction, a divergence from its +14.65 point 1-year outperformance.
- Credit-quality concerns cloud the recovery: Recent coverage explicitly flags credit risks as the reason for caution, and the wide analyst target spread — $65.00 low to $87.00 high, about 34% of the current price — signals genuine disagreement about the credit cycle rather than the business model. The low target of $65.00 implies only 2.8% upside and effectively prices in credit normalization.
- ROE of 6.96% remains structurally weak: A 6.96% return on equity and 0.99% return on assets are improving but still below what a well-run regional bank should earn through a cycle. At 0.96x book value, further upside now depends on ROE improvement toward 10%+ rather than multiple expansion, since the P/B re-rating from the 0.53x Q2 2023 trough has already been largely captured.
- Forward EPS estimate carries execution risk: The 9.74x forward PE rests on consensus EPS of $5.74, a roughly 36% increase from trailing levels, so the cheap-looking multiple is contingent on the earnings recovery holding. If credit costs normalize higher, the forward estimate is at risk and the stock would re-rate toward its recent 11.2x–13.4x trailing band rather than the current 14.98x.
CFG Technical Analysis
CFG is in a recovery-turned-consolidation phase rather than a clean uptrend. The stock is up 24.24% over the past year and 6.48% year-to-date, but at $63.24 it sits at roughly 54.6% of its 52-week range of $49.00 to $75.33 — squarely in the middle of the band, neither momentum-extended nor a falling knife. The 1-year relative strength versus SPY of +14.65 percentage points confirms genuine outperformance, yet the failure to hold the July–August highs near $74.73 signals that the market is no longer willing to pay up for the recovery story without fresh evidence. Recent momentum is the key tension: the stock is up just 0.27% over the past month but down 12.98% over three months, a sharp deceleration from the 1-year trend. That divergence — long-term strength against a three-month drawdown of nearly 13% — points to a corrective phase rather than a trend reversal, especially since the 1-month relative strength of +5.26 points versus SPY's -4.99% shows CFG outperforming a weak tape. The stock has stabilized in a $62.57–$65.90 range through October and early November, suggesting sellers are being absorbed, but the absence of a decisive bounce leaves the near-term setup neutral. Key levels are well defined: support sits at the $62.57 October low and, more importantly, the $49.00 52-week low, while resistance is the $74.73 August high and the $75.33 52-week high. A breakout above $75 would confirm resumption of the primary uptrend and likely trigger momentum buying, whereas a breakdown below $62.50 would open the door to a retest of the $60 area and undermine the recovery thesis. With a beta of 1.095, CFG is only about 10% more volatile than the market — modest for a bank — but the -18.32% max drawdown shows it can still deliver meaningful peak-to-trough pain, so position sizing should account for a stock that trades with the financials complex rather than as a defensive holding.
Beta
1.09
1.09x market volatility
Max Drawdown
-18.3%
Largest decline past year
52-Week Range
$49-$75
Price range past year
Annual Return
+25.2%
Cumulative gain past year
| Period | CFG Return | S&P 500 |
|---|---|---|
| 1m | +2.3% | -2.4% |
| 3m | -11.8% | -2.3% |
| 6m | +7.4% | +2.8% |
| 1y | +25.2% | +11.3% |
| ytd | +10.1% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CFG Fundamental Analysis
The revenue trajectory is clearly positive and, importantly, accelerating. Q3 2026 revenue of $3.268 billion grew 5.83% year-over-year versus $3.088 billion in Q3 2025, and the sequential path — $2.896B (Q1'25) → $3.007B (Q2'25) → $3.088B (Q3'25) → $3.026B (Q4'25) → $3.026B (Q1'26) → $3.195B (Q2'26) → $3.268B (Q3'26) — shows three consecutive quarters of sequential growth and a record top line. Net interest income is benefiting from a favorable rate backdrop, with interest income rising to $2.621 billion in Q3'26 from $2.458 billion a year earlier while interest expense fell to $946 million from $970 million, a classic margin-expansion setup. Fee businesses remain a smaller but stable contributor, with card fees of $86 million and service charges of $119 million, and the growth trend supports the investment case for a bank executing on both spread and fee levers. Profitability has inflected decisively. Q3 2026 net income of $636 million compares with $494 million a year ago, a 28.7% increase, and net margin expanded to 19.46% from 16.00% — the best level in the dataset. Gross margin has climbed steadily from 63.60% in Q3'25 to 67.23% in Q3'26, while operating margin reached 24.60% from 20.37%, and EPS rose to $1.42 from $1.06. The quarterly progression of net income — $373M → $436M → $494M → $528M → $517M → $587M → $636M — is remarkably consistent, and the 20.9% effective tax rate and 79.1% net-income-to-pretax conversion are healthy for a regional bank. Balance sheet and cash flow metrics are solid but require nuance. Debt-to-equity of 0.4287 is conservative for a bank, ROE of 6.96% and ROA of 0.99% are improving but still below what a well-run regional bank should earn through a cycle, and the 3.52% dividend yield with a 48.5% payout ratio is well covered. Free cash flow TTM of $1.093 billion against a $25.2 billion market cap implies an FCF yield of roughly 4.3%, and quarterly operating cash flow has been volatile ($453M in Q3'26, $726M in Q2'26, $237M in Q1'26, -$158M in Q4'25) due to working-capital and securities-portfolio flows typical of banks. The company returned capital aggressively — $231 million in dividends and $125 million in buybacks in Q3'26 alone — while still growing cash to $12.97 billion, indicating internal funding capacity rather than reliance on external financing.
Quarterly Revenue
$3.3B
2026-09
Revenue YoY Growth
+5.8%
YoY Comparison
Gross Margin
67.2%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CFG Overvalued?
Because CFG is solidly profitable — Q3 2026 net income of $636 million and trailing EPS of $1.42 — the PE ratio is the appropriate primary metric. The stock trades at 14.98x trailing earnings but only 9.74x forward earnings, a 35% compression that implies the market expects EPS to grow from roughly $4.22 trailing to the $5.74 consensus estimate, a ~36% increase. That gap is the crux of the valuation debate: if the earnings recovery holds, the forward multiple is cheap; if credit costs normalize higher, the forward estimate is at risk. On a price-to-book basis, CFG trades at 0.957x — below tangible book — which for a bank earning a 6.96% ROE is neither a bargain nor a warning, but rather a fair reflection of mid-single-digit returns. Peer comparison is constrained because the provided valuation dataset does not include an explicit industry-average multiple, so a precise premium/discount spread cannot be quantified; however, the internal evidence is telling. A 0.96x P/B and 9.74x forward PE are consistent with a regional bank valued at or slightly below book, while the 2.26x PS ratio and 8.46x EV/EBITDA sit in a reasonable range for the sector. The 0.53 PEG ratio suggests the stock is inexpensive relative to its growth rate, and the 3.52% dividend yield provides a meaningful carry that supports the total-return case even if multiple expansion stalls. Historically, CFG's PE has ranged from roughly 7.0x in mid-2023 to 24.4x in Q4 2023, with the more recent quarters clustering between 11.2x and 13.4x; at 14.98x trailing, the stock is near the upper end of its recent band but far below the 2023 spike. Its P/B history is more instructive: the ratio troughed near 0.53x in Q2 2023 and has since recovered to 0.96x, meaning the market has already re-rated the franchise substantially off the pessimism lows. That argues the easy money from the book-value re-rating has been made, and further upside now depends on ROE improvement toward 10%+ rather than multiple expansion.
PE
15.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 7x~14x
vs. Industry Avg
12.0x
Industry PE ~12.0x*
EV/EBITDA
8.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the durability of the earnings recovery and the quality of the loan book. The 9.74x forward PE depends on EPS rising roughly 36% from trailing levels to the $5.74 consensus, so any upward normalization in credit costs would hit both the estimate and the multiple at once. ROE of 6.96% and ROA of 0.99% remain below cycle-appropriate levels, meaning the franchise is not yet earning enough to justify much multiple expansion, and quarterly operating cash flow has been volatile — -$158 million in Q4 2025 versus $726 million in Q2 2026 — reflecting working-capital and securities-portfolio swings typical of a bank. Revenue is also concentrated in spread income, with interest income of $2.621 billion dwarfing card fees of $86 million and service charges of $119 million, leaving results sensitive to rate and deposit-cost shifts.
Market and competitive risks revolve around valuation compression and sector rotation. At 14.98x trailing earnings the stock sits near the upper end of its recent 11.2x–13.4x band, so a re-rating back toward that range would erase much of the analyst-implied upside even without an earnings miss. The 0.96x price-to-book has already recovered from the 0.53x Q2 2023 trough, meaning the easy book-value re-rating has been captured and further gains require ROE improvement rather than multiple expansion. With a beta of 1.095, CFG trades with the financials complex rather than as a defensive holding, and the 3-month relative strength of -8.07 points versus SPY shows it can lag sharply when the sector rotates; peer commentary such as KeyCorp's raised 2026 revenue outlook highlights that loan growth and margin expansion are contested across regional banks.
In a worst-case scenario, credit normalization accelerates, the $5.74 forward EPS estimate is cut, and the stock re-rates toward its recent low-end multiple while the sector rotates away from banks. A retest of the $49.00 52-week low would represent roughly -22.5% from the current $63.24, while the analyst low target of $65.00 implies only 2.8% upside and effectively caps the downside case near current levels in the near term. The stock's -18.32% max drawdown provides a realistic reference for peak-to-trough pain, and a break below the $62.57 October low would open the door to the $60 area and undermine the recovery thesis. Position sizing should assume a -20% to -25% adverse move is plausible if the credit cycle turns.
FAQ
The most severe risk is credit normalization: the 9.74x forward PE depends on $5.74 of forward EPS, roughly 36% above trailing, so rising provisions would cut the estimate and compress the multiple at once, with a retest of the $49.00 52-week low implying about -22.5%. Second is multiple compression — at 14.98x trailing the stock is near the top of its 11.2x-13.4x recent band, and a reversion would erase much of the analyst-implied upside even without an earnings miss. Third is structural profitability: ROE of 6.96% and ROA of 0.99% remain below cycle-appropriate levels, limiting how much further the 0.96x book valuation can expand. Fourth is macro and sector sensitivity — a beta of 1.095 and a -8.07 point three-month relative strength versus SPY show CFG trades with the financials complex and can lag sharply during sector rotation, as the -18.32% max drawdown illustrates.
The base case carries 55% probability with a $65.00-$76.39 range, assuming the $5.74 forward EPS consensus is broadly met, credit costs rise modestly without forcing estimate cuts, and the multiple holds near 9.7x-11x forward earnings as the stock grinds toward the $76.39 average target. The bull case at 25% probability targets $76.39-$87.00, requiring credit provisions to flatten or decline, continued net interest margin expansion from lower deposit costs, and a re-rating toward 1.2x+ book value. The bear case at 20% probability spans $49.00-$65.00, driven by faster credit normalization, a break below the $62.57 October low, and sector rotation away from spread lenders. The base case is most likely, and its key assumption is that the earnings recovery holds without a credit-driven estimate cut — the single variable that would most change the forecast.
CFG screens modestly undervalued on forward earnings but fairly valued on book. The 14.98x trailing PE compresses to 9.74x forward, a 35% gap that implies the market expects EPS to climb from roughly $4.22 trailing to the $5.74 consensus, and the 0.53 PEG ratio suggests the stock is inexpensive relative to that growth. However, the 0.96x price-to-book is a fair reflection of a 6.96% ROE — the ratio has already recovered from the 0.53x Q2 2023 trough, so the easy book-value re-rating has been captured. At 14.98x trailing, the stock sits near the upper end of its recent 11.2x-13.4x band, meaning the market is paying a modest premium to its own recent history but far below the 24.4x Q4 2023 spike. The valuation implies the market expects the earnings recovery to hold but is not yet willing to pay for a full ROE normalization toward 10%+.
On a risk/reward basis the setup is favorable but not exceptional. The stock at $63.24 offers 20.8% upside to the $76.39 average analyst target, with 17 of 19 analysts rating Buy and none rating Sell, while trading at just 9.74x forward earnings and 0.96x book value. The downside is bounded in the near term by the $65.00 analyst low target (only 2.8% upside, effectively a flat-to-modest outcome) but extends to roughly -22.5% if the stock retests its $49.00 52-week low on a credit deterioration. The biggest risk is that the cheap forward multiple rests on a $5.74 EPS consensus requiring roughly 36% growth from trailing levels — if credit provisions rise, estimate and multiple compress together. It is a good buy for value-oriented investors with a 12-18 month horizon who accept bank-sector cyclicality and can size positions for a -20% to -25% adverse move; it is less suitable for investors seeking low volatility or near-term momentum, given the 12.98% three-month drawdown.
CFG is better suited to a medium-to-long-term holding period of at least 12-18 months than to short-term trading. The thesis is an earnings-recovery and ROE-normalization story that plays out over several quarters, and the 3.52% dividend yield with a 48.5% payout ratio rewards patience with meaningful carry while the multiple works itself out. Short-term traders face a neutral technical setup — the stock sits at roughly 54.6% of its 52-week range, has stabilized in a $62.57-$65.90 band, and shows conflicting signals with a +5.26 point one-month relative strength against a -8.07 point three-month figure. Volatility is moderate for a bank (beta 1.095) but the -18.32% max drawdown means position sizing matters. A concrete minimum holding period of 12 months aligns with the base-case timeline for the stock to approach the $76.39 average target.